1. Home
  2. NL vs CBIO Comparison

NL vs CBIO Comparison

Compare NL & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NL
  • CBIO
  • Stock Information
  • Founded
  • NL 1891
  • CBIO 2003
  • Country
  • NL United States
  • CBIO United States
  • Employees
  • NL N/A
  • CBIO N/A
  • Industry
  • NL Major Chemicals
  • CBIO
  • Sector
  • NL Industrials
  • CBIO
  • Exchange
  • NL Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • NL 320.5M
  • CBIO 308.0M
  • IPO Year
  • NL N/A
  • CBIO N/A
  • Fundamental
  • Price
  • NL $6.52
  • CBIO $13.92
  • Analyst Decision
  • NL Sell
  • CBIO Strong Buy
  • Analyst Count
  • NL 1
  • CBIO 4
  • Target Price
  • NL $6.00
  • CBIO $25.50
  • AVG Volume (30 Days)
  • NL 38.6K
  • CBIO 94.8K
  • Earning Date
  • NL 08-06-2025
  • CBIO 07-31-2025
  • Dividend Yield
  • NL 5.52%
  • CBIO N/A
  • EPS Growth
  • NL 141.37
  • CBIO N/A
  • EPS
  • NL 1.10
  • CBIO N/A
  • Revenue
  • NL $152,721,000.00
  • CBIO N/A
  • Revenue This Year
  • NL $15.75
  • CBIO N/A
  • Revenue Next Year
  • NL $2.44
  • CBIO N/A
  • P/E Ratio
  • NL $5.98
  • CBIO N/A
  • Revenue Growth
  • NL N/A
  • CBIO N/A
  • 52 Week Low
  • NL $5.29
  • CBIO $10.83
  • 52 Week High
  • NL $9.42
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • NL 54.00
  • CBIO N/A
  • Support Level
  • NL $5.70
  • CBIO N/A
  • Resistance Level
  • NL $6.77
  • CBIO N/A
  • Average True Range (ATR)
  • NL 0.36
  • CBIO 0.00
  • MACD
  • NL 0.07
  • CBIO 0.00
  • Stochastic Oscillator
  • NL 82.58
  • CBIO 0.00

About NL NL Industries Inc.

NL Industries Inc is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: